Home | Contact | Sitemap | 中文 | CAS
Home | About Us | Research | News | International Cooperation | Academicians | Our Groups | Join Us | Publications | Papers | Education & Training | Resources
Home
About Us
Research
Academicians
International Cooperation
News
Education & Training
Join Us
Societies & Publications
Papers
Resources
Links
Sitemap
Location: Home > Research > Research Progress
TEXT SIZE: A A A PRINTER CLOSE
Important Breakthrough Made in Developing New Potential Anticancer Drugs
source:     author:     2009-09-22

    In collaboration with State Key Laboratory of Medical Genomics in Shanghai Jiao Tong University, Shanghai Institutes for Biological Sciences in CAS, and Rui Jin Hospital, Prof. Sun Handong, academician of CAS, observed significant apoptosis of t (8; 21) chromosome translocation through NF-κB and MAPK pathways, concomitant with caspase-3 activation. AML1-ETO oncoprotein was degraded in parallel to caspase-3 activation. The study was published in the journal of Cell Death and Differentiation (2007, 14(2), 306-317). Through profound studies on the medicinal mechanism of eriocalyxin B (EriB), which was tested on AML-M2b leukemia cells, the researchers concluded that Kasumi-1 and AML-M2b murine leukemia cells were most sensitive to EriB (even at μM level) with significant apoptosis. EriB-mediated apoptosis was associated with NF-κB inactivation by preventing NF-κB nuclear translocation and EriB was effective on primary t(8;21) leukemia blasts and caused AML1-ETO degradation. The high-degree selectivity and low-concentration medical effect suggested that EriB might be a low-toxicity, high-performance molecular-targeted agent, with great potential to candidate drug for targeting therapy of AML-M2b type leukemia.

 


Copyright © 2002-2016 Kunming Institute of Botany, CAS All Rights Reserved.
Address: 132# Lanhei Road, Heilongtan, Kunming 650201, Yunnan, China
Tel: +86 871 65223223 Fax: +86 871 65223223 Other Contact Information